A Leading Global Molecular Diagnostic Platform

A best-in-class global molecular diagnostic platform to democratize point of care and home use testing, thus contributing to the prevention of infectious disease transmission and better health for the citizens of the world.

Our Mission

  • Contribute to the early detection and prevention of infectious disease transmission

  • Leverage our proprietary AntiSense molecular RNA diagnostic platform across multiple infectious disease diagnostic categories

  • Create highly accurate, quick, affordable, easy to administer and minimally invasive disease diagnostic test kits that will democratize testing for use at point of care and in home

LEARN MORE

Our PRODUCTS

  • The Company’s first products are AntiSense molecular diagnostic test kits that accurately, quickly and affordably detect respiratory infections, including Covid-19 in less than 5 minutes

  • Our AntiSense molecular diagnostic test delivers the gold standard testing accuracy of a RT-PCR test, with the speed of the fastest rapid tests

  • The AntiSense molecular diagnostic platform will be further expanded for use in testing for other infectious diseases

LEARN MORE

COVID-19

  • 1 billion Covid-19 molecular tests administered globally in 2020

  • Click here for link to Health Canada Covid-19 Infobase

  • Click here for link to US Government CDC Covid-19 Tracker Data

  • Click here for link to University of Oxford – Our World in Data Global Database

RNA Disease Diagnostics Secures Exclusive License to Ground-Breaking RNA-Based Molecular Lateral Flow Assay Technology

November 9, 2021

RNA Disease Diagnostics, Inc. (“RNADD” or the “Company”), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today that it has secured an exclusive global license to a rapid ribonucleic acid (“RNA”)-based molecular Lateral Flow Assay (“LFA”) technology jointly owned by the University of Maryland, Baltimore (“UMB”) and the University of Maryland, Baltimore County (“UMBC”).

Read More

Board-Certified Internist and Renowned Professional Sports Team Physician, Dr. Michael S. Farber, Joins RNA Disease Diagnostics’ Advisory Board

September 2, 2021

RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today the appointment of Michael S. Farber, M.D. to its Advisory Board.

Read More

Exclusive Global License

Investors

We have established a world class executive leadership team, Board of Directors and Board of Advisors, with experience in healthcare, life sciences, medical devices, diagnostics, biotechnology, nanomedicine, drug delivery, and pharmaceuticals. Our financial advisors have decades of global experience in investment banking in the private and public sector.

LEARN MORE